| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
SIRT2-IN-8 targets SIRT2, a NAD⁺-dependent deacetylase implicated in cellular processes including apoptosis, inflammation, and stress resistance. SIRT2 is involved in the pathogenesis of neurodegenerative diseases such as Huntington's and Parkinson's diseases.
|
|---|---|
| ln Vitro |
In vitro, SIRT2-IN-8 is a potent SIRT2 inhibitor. It is a cell-permeable inhibitor of sirtuin 2. SIRT2-IN-8 can be used for research in Huntington's and Parkinson's diseases.
|
| ln Vivo |
In vivo data for SIRT2-IN-8 are limited in the available literature. As a SIRT2 inhibitor, it may have potential for research in neurodegenerative diseases. Further in vivo studies are needed to evaluate its therapeutic potential.
|
| Enzyme Assay |
SIRT2-IN-8's SIRT2 inhibition activity can be characterized using biochemical assays with purified SIRT2 enzyme. The compound's ability to inhibit SIRT2-mediated deacetylation of substrates can be measured. Selectivity over other sirtuin isoforms can be assessed.
|
| Cell Assay |
In vitro cell experiments with SIRT2-IN-8 involve treating neuronal cells with the compound and assessing its effects on SIRT2 activity, protein acetylation, and cell survival. The compound's potential neuroprotective effects can be evaluated in models of Huntington's and Parkinson's diseases.
|
| Animal Protocol |
In vivo animal studies with SIRT2-IN-8 have been conducted using models of Huntington's and Parkinson's diseases. The compound is typically administered via injection. Detailed protocols regarding dosage, treatment duration, and specific animal models are not extensively reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data specific to SIRT2-IN-8 are limited in the available literature. As a small molecule with a molecular weight of 396.83, the compound is expected to have reasonable bioavailability. Further pharmacokinetic studies are needed.
|
| Toxicity/Toxicokinetics |
SIRT2-IN-8 is considered safe for research use at typical concentrations. As a research compound, it is intended for laboratory use only and not for human consumption. The compound should be handled under standard laboratory safety practices.
|
| References | |
| Additional Infomation |
(4-Chlorophenyl)-[4-(8-nitro-5-quinolinyl)-1-piperazinyl] methyl ketone is an N-arylpiperazine.
SIRT2-IN-8 is a potent SIRT2 inhibitor. It can be used for research in Huntington's and Parkinson's diseases. It has a molecular formula of C₂₀H₁₇ClN₄O₃ and a molecular weight of 396.83. It is also designated as B2 or CPNQ. |
| Molecular Formula |
C20H17N4O3CL
|
|---|---|
| Molecular Weight |
396.82698
|
| Exact Mass |
396.099
|
| CAS # |
115687-05-3
|
| PubChem CID |
3953303
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.4±0.1g/cm3
|
| Boiling Point |
645.5±55.0°C at 760 mmHg
|
| Flash Point |
344.2±31.5°C
|
| Index of Refraction |
1.687
|
| LogP |
4.284
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
28
|
| Complexity |
570
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KLNPVNZJCWIQSK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H17ClN4O3/c21-15-5-3-14(4-6-15)20(26)24-12-10-23(11-13-24)17-7-8-18(25(27)28)19-16(17)2-1-9-22-19/h1-9H,10-13H2
|
| Chemical Name |
(4-chlorophenyl)-[4-(8-nitroquinolin-5-yl)piperazin-1-yl]methanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~126.00 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5200 mL | 12.5999 mL | 25.1997 mL | |
| 5 mM | 0.5040 mL | 2.5200 mL | 5.0399 mL | |
| 10 mM | 0.2520 mL | 1.2600 mL | 2.5200 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
